Fluorescence in situ hybridization analysis of CCND3 gene as marker of progression in bladder carcinoma

Journal of Biological Regulators and Homeostatic Agents

Volumn 27, Issue 2, 2013, Pages 559-567

  Lopez Beltran, Antonio ^a   Ordonez J L ^b   Otero, A P ^b   Blanca, A ^c   Sevillano, V ^b   Sanchez Carbayo, M ^d   Kirkali, Z ^e   Cheng, L ^f   Montironi, R ^g   Prieto, R ^c   De Alava, E ^b,h  

^a Universidad de Cordoba   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Bladder cancer; CCND3; Cyclin D3; FISH; Gene amplification; Immunohistochemistry

Indexed keywords

CYCLIN D3; CCND3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; BLADDER TUMOR; DISEASE COURSE; GENETICS; LETTER; METHODOLOGY; MIDDLE AGED; MORTALITY;

AGED; CYCLIN D3; DISEASE PROGRESSION; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84883507940     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lopez-Beltran A. Bladder cancer: clinical and pathological profile Scand J Urol Nephrol Suppl 2008; 218:95-9.
2. Eble JN, Sauter G, Epstein JI, Sesterhenn IAE. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press Lyon 2004.
3. Lopez-Beltran A, Montironi R. Non-Invasive Urothelial Neoplasms: According to the most recent WHO classification. Eur Urol 2004; 46:170-6. (Pubitemid 38902731)
4. Mazzucchelli R, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. Classification and grading of noninvasive and invasive neoplasms of the urothelium. Anal Quant Cytol Hitol 2012; 34:111-9.
5. Cheng L, Zhang S, Davidson DD, et al. Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol. 2009; 5:843-57.
6. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Lopez-Beltran A. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma, Cancer Lett 2007; 250:292-9. (Pubitemid 46529448)
7. Zlotta AR, Noel JC, Fayt I. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy J Urol 1999; 161:792-8 (Pubitemid 29422368)
8. Lopez-Beltran A, Cheng L, Mazzucchelli R, Blanca A, Montironi R. Morphological and Molecular Profiles and Pathways in Bladder Neoplasms. Anticancer Res 2008; 28:2893-0
9. Schrier BP, Vriesema JL, Witjes JA, Kiemeney LA, Schalken JA. The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol 2006; 50:76-2
10. Lopez-Beltran A, Requena MJ, RJ Luque, Alvarez J, Montironi R. Cyclin D3 expression in primary Ta/T1 bladder cancer J Pathol 2006; 209:106-3.
11. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Montironi R. Prognostic Factors in StageT1Grade 3 Bladder Cancer Survival: The Role of G1+SModulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and Proliferation Index (ki67-MIB1). Eur Urol 2004; 45:606-2.
12. Bartkova J, Zemanova M, Bartek J. Abundance and subcellular localization of cyclin D3 in human tumors Int J Cancer 1996; 65:323-7. (Pubitemid 26059986)
13. Pruneri G, Pignataro L, Valentini S. Cyclin D3 Immunoreactivity Is an Independent Predictor of Survival in Laryngeal Squamous Cell Carcinoma. Clin Cancer Res 2005; 11:242-8. (Pubitemid 40075801)
14. Petty WJ, Voelzke WR, Urbanic JJ, et al. High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer 2011; 74:384-1.
15. Levidou G, Saetta AA, Karlou M et al. D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. J Cancer Res Clin Oncol 2010; 136:1563-71.
16. Lopez-Beltran A, Ordóñez JL, Otero AP, et al. Cyclin D3 gene amplification in bladder carcinoma in situ. Virchows Arch 2010; 457:555-61.
17. Corteggio A, Urraro C, Roperto S, Roperto F, Borzacchiello G. Phosphatidylinositol-3-kinase-AKT pathway, phospho-JUN and phospho-JNK expression in spontaneously arising bovine urinary bladder tumours. J Comp Pathol 2010; 143:173-8.
18. Yang F, Jove V, Buettner R, et al. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biol Ther 2012; 13:534-41.
19. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003; 61:1140-5. (Pubitemid 36693989)
20. Hopman AH, Kamps MA, Speel EJ, Schapers RF, Sauter G, Ramaekers FC. Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma. Am J Pathol 2002; 161:1119-25.
21. Shariat SF, Pahlavan S, Baseman AG. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology 2001; 57:60-5. (Pubitemid 32065821)
22. Birkhahn M, Mitra AP, Williams AJ. Predicting Recurrence and Progression of Noninvasive Papillary Bladder Cancer at Initial Presentation Based on Quantitative Gene Expression Profiles Eur Urol 2010; 57:12-20.
23. Song YA, Park YL, Kim KY, et al. RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer. Pathol Int 2012; 62:127-6.
24. Wang X, Sistrunk C, Miliani de Marval PL, Kim Y, Rodriguez-Puebla ML. Combined effect of cyclin D3 expression and abrogation of cyclin D1 prevent mouse skin tumor development. Cell Cycle 2012; 11:335-42.
25. Zhang Q, Sakamoto K, Liu C, et al. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression. Cancer Res 2011; 71:7513-4.
26. Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 2012; 33:1113-20.